Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYHA1813 + SG001
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
SYHA1813 + SG001 is an investigational combination therapy composed of SYHA1813, an oral small-molecule multikinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) and colony-stimulating factor 1 receptor (CSF1R), used for its antiangiogenic and immunomodulatory effects, and SG001 (also known as enlonstobart), a biological agent under clinical development, often in the context of combination protocols for solid tumors. This combination is being assessed in clinical trials for the treatment of advanced solid tumors, high-grade gliomas, small cell lung cancer, renal cell carcinoma, and other indications. The rationale for this combination is to synergize anti-angiogenic actions (via VEGFR blockade) with modulation of the tumor immune microenvironment (via CSF1R and possible complementary actions of SG001).
- Other names
- SYHA1813 + SG001
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on SYHA1813 + SG001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYHA1813 + SG001.